Tianfeng Securities has given Oulin Bio an “buy” rating. The supply of tetanus vaccine continues to increase, and the Staphylococcus aureus vaccine is about to enter the harvest period
August 19, 2025
Source: drugdu
91
Tianfeng Securities released a research report on August 18th, giving Oulin Bio (688319.SH, latest price: 23.99 yuan) an "overweight" rating. The main reasons for the rating include: 1) The adsorbed tetanus vaccine has been continuously increasing in supply, and the market size has gradually expanded; 2) The research and development progress of Staphylococcus aureus vaccine is leading globally, and the future market prospects are broad. 3) The Helicobacter pylori vaccine has obtained the approval for Phase 1 clinical trials in Australia. Risk Warning: Risk of R&D investment, risk of failure in the development of in-progress products, risk of commercialization not meeting expectations, risk of leakage of core technologies, risk of stock price fluctuations.
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
